You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Design and Development of Immunotolerant S. aureus Biotherapies
SBC: Lyticon LLC Topic: RThe increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF
SBC: CELDARA MEDICAL, LLC Topic: NHLBIDESCRIPTIONprovided by applicantIdiopathic pulmonary fibrosisIPFkills aboutpersons in the United States each yearThere are currently aroundAmericans afflicted with this fatal disease that typically results in death withinyearsThis year alone another approximatelyAmericans will receive this devastating diagnosisWhile two recently approved drugs reduce the time to decline in certain lung parametersa ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of GIFT4: a B cell focused immunotherapy for cancer
SBC: CELDARA MEDICAL, LLC Topic: NCIProject Summary Our goal is to develop a novel immunotherapy for the treatment of melanomaand potentially a wide array of tumorsAlthough surveillance by the immune system eliminates cancer cells in some instancestumor cells have developed a variety of mechanisms to escape immune recognition often resulting in tumor outgrowthImmune checkpoint inhibitorse gipilimumabnivolumaband pembrolizumaband cel ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Precision quality check of immunotherapeutics via single-cell cytokine mapping
SBC: ISOPLEXIS CORPORATION Topic: 102Adoptive transfer of autologous T cells engineered to express chimeric antigen receptorsCARshas emerged as a promising immunotherapy for patients with hematologic malignanciessuch as CDCARs in leukemias and lymphomasHoweverchallenges remain in terms of manufacturing consistency and the functional profile of the CAR T cell productsince infused cellsasliving drugscan be activated and release a varie ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Long non-coding RNA signatures to classify multiple sclerosis
SBC: IQuity Labs, Inc. Topic: NIAIDDiagnosis of relapsing remitting multiple sclerosisMSrests on clinical symptoms and examinations asoutlined in the revised McDonald s criteria supported by appropriate magnetic resonance imaging findings andother laboratory testsThe need for early diagnosis is clearly emphasized in a position paper produced inby MS Brain Health organization calledBrain healthTime matters in multiple sclerosiswhich ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Improved Thermal and Acoustic Comfort for Motorcycle Helmets
SBC: CREARE LLC Topic: 151NH1Use of motorcycles helmets significantly reduces the risk of fatality or serious brain injury to riders in the event of a crash, but riders often do not wear helmets in warm weather because of thermal discomfort. We propose to develop an innovative ventilation and cooling system that will maintain a cool, dry environment inside the helmet while also meeting applicable safety standards. The key the ...
SBIR Phase II 2017 Department of Transportation -
A Hand-Held Robot to Cure BPH
SBC: VIRTUOSO SURGICAL, INC. Topic: NIBIBProject Summary AbstractThe objective of this proposal is to transform a hand held surgical robotic system for transurethral laser prostate surgery from a lab prototype into a commercial productThe system will feature needle sized arms deployed through the endoscope port and will enable independent tissue manipulationlaser aimingand visualizationmaking surgery more accurate and ef cientClinical si ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine
SBC: 490 BIOTECH INC Topic: 400Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable th ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
SBC: Immunext, Inc. Topic: RImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly successful negative checkpoint regulatorNCRfamily of drug targetswhose members have demonstrated proven efficacy in inducing long term remissions in human cancersWe contend that antibodies that suppres ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health